Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the ...
Tag: Lucentis
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of ...